查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138283

2022-2029 年全球全外显子组测序 (WES) 市场

Global Whole Exome Sequencing [WES] Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

全球全外显子组测序 (WES) 市场的增长受到多种因素的推动，例如对罕见病诊断的需求不断增加、基因组学和下一代测序领域的研发不断增加，以及对个性化医疗的需求不断增加。由

全外显子组测序 (WES) 的日益普及正在推动全球市场的增长。

越来越多地采用新一代测序方法来预测、治疗和监测包括癌症在内的各种慢性病，正在推动全球市场的增长。癌症外显子组测序提供了有关导致肿瘤进展的编码突变的有价值信息。由于外显子组占基因组的比例不到 2%，因此癌症外显子组测序是全基因组测序的一种经济有效的替代方案。此外，与全基因组方法相比，外显子组测序提供了更方便的数据集。此外，全外显子组测序技术的低成本和高速度、全外显子组测序技术的技术进步以及全球主要研究机构的战略联盟也在推动全外显子组测序市场的增长。例如，2021 年 5 月，Baylor Genetics 推出了 Rapid Trio Whole Exome Sequencing，将周转时间从 7 天缩短到 5 天。此外，纽约大学的一项研究发现，全外显子组测序可以预测患者是否对癌症免疫疗法有反应。

缺乏熟练的人力和缺乏政府支持是全外显子组测序 (WES) 全球市场增长的障碍。

然而，熟练专业人员的短缺和对政府补贴的高度依赖正在抑制整个外显子组测序市场的增长。

行业分析

全球全外显子组测序 (WES) 市场报告根据波特五力、创新、新产品发布、定价分析等各种行业因素对市场进行了深入分析。

COVID-19 影响分析

COVID-19 为全外显子组测序 (WES) 市场提供了新机遇。例如，COVID-19 正在推动我们实践数字护理的新现实。确定特定基因型与感染风险之间的关係表明，迫切需要虚拟护理干预措施，以最大限度地减少大流行期间的干扰并减少获得医疗保健的机会。此外，大流行后，对数字医疗保健解决方案的资金增加对全球全外显子组测序 [WES] 市场的增长产生了积极影响。

全球全外显子组测序 [WES] 市场报告将提供对大约 40 多个市场数据表、45 多个数字和估计 200 页的访问。

内容

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 采用率提高
      • 激活研发
    • 限制因素
      • 缺乏熟练的专业人员
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品/服务分类

  • 系统
  • 套件
    • 库准备工具包
    • 目标丰富工具包
    • 其他
  • 服务内容
    • 测序服务
    • 数据分析（生物信息学）服务
    • 其他服务

第 8 章技术

  • 二代测序
    • 合成方法测序 (SBS)
    • 杂交连接测序 (SBL)
  • 第三代测序仪

第 9 章。按应用程序

  • 药物发现和药物开发
  • 诊断
  • 个性化医疗
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章公司简介

  • 安捷伦科技公司
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Illumina Inc.
  • Bio-Rad Laboratories Inc.
  • Macrogen Inc.
  • Beijing Genomics Institute
  • Ambry Genetics Corp.
  • Eurofins Scientific Group
  • F. Hoffmann-La Roche AG
  • GENEWIZ Inc.
  • Pacific Biosciences of California Inc.

第13章 DataM

简介目录
Product Code: DMPH2134

Market Overview

Whole Exome Sequencing [WES] Market is expected to grow at a CAGR of 18.6% during the forecasting period (2022-2029).

Whole exome sequencing is a commonly used next-generation sequencing (NGS) procedure that involves sequencing protein-coding regions of the genome. The human exome represents less than 2% of the genome but contains about 85% known disease-related variants, making this method a cost-effective alternative to whole-genome sequencing. Exome sequencing is widely used to identify and determine genetic variants causing various diseases, such as Miller syndrome and Alzheimer's disease. It also provides a cost-effective screening approach for the diagnosis of genetic disorders. It presents a less resource-intensive alternative to whole-genome sequencing in several applications, including drug discovery and development.

Market Dynamics

The global whole exome sequencing [WES] market growth is driven by several factors, such as increasing demand for the diagnosis of rare diseases, rising research and development in the genomics and next-generation sequencing field, and growing demand for personalized medicine.

The increasing adoption of Whole Exome Sequencing [WES] propels the global market growth.

The rising adoption of next-generation sequencing methods for predicting, treating, and monitoring various chronic diseases, such as cancer, is boosting the market's growth globally. Sequencing the cancer exome provides valuable information about the coding mutations contributing to tumor progression. As the exome represents less than 2% of the genome, cancer exome sequencing is a cost-effective alternative to whole-genome sequencing. Exome sequencing also produces a more convenient data set compared to whole-genome approaches. In addition, the low cost and high speed associated with whole-exome sequencing technology, technological advancements in whole-exome sequencing techniques, and strategic alliances among leading research institutes globally, are also driving the growth of the whole-exome sequencing market. For instance, In May 2021, Baylor Genetics introduced Rapid Trio Whole Exome Sequencing, reducing its turnaround time from seven to five days. Moreover, according to the New York University research, Whole Exome Sequencing Predicts Whether Patients Respond to Cancer Immunotherapy.

The lack of skilled personnel and deprived government support are hurdles to the global Whole Exome Sequencing [WES] market growth.

However, the lack of skilled professionals and high dependability on government grants are restraining the growth of the whole-exome sequencing market.

Industry analysis.

The global whole exome sequencing [WES] market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, Etc.

COVID-19 Impact Analysis

COVID-19 has provided the Whole Exome Sequencing [WES] market with emerging opportunities. For instance, COVID-19 has encouraged us to practice the new reality of digital care. During the pandemic, it was revealed that there is an urgency for virtual care interventions to reduce the interruptions to a minimum and to minimize compromised access to healthcare, which caused increased focus on the sequencing methods for identification of relationships between particular genotypes with the risk of infection. Furthermore, post-pandemic, there is a rise in funding for digital healthcare solutions, positively impacting the global Whole Exome Sequencing [WES] market growth.

Segment Analysis

The Whole Exome Sequencing [WES] application in personalized medicine is predicted to have the largest global market share during the forecast period (2022-2029).

Personalized medicine is expected to grow at the highest rate during the forecast period (2022-2029). Since it aims to provide tailor-made therapies to individual patients, depending on the molecular basis of the disease, it has become popular over recent years. The rising demand for personalized medicine has created tremendous opportunities in genetic medicine. To exploit these opportunities, novel diagnostic and therapeutic technologies must be developed, resulting in the rapid expansion of the global whole exome sequencing market. Growing research & development in precise detection and diagnosis of the disease is expected to minimize the cost of treating chronic conditions. Advancements in whole genome sequencing and molecular diagnostics have given health sciences a better understanding of the precise nature of diseases and pathways to develop personalized treatments.

Geographical Analysis

The North American region commands the global Whole Exome Sequencing [WES] market during the forecast period (2022-2029).

North America is dominating the global whole exome sequencing [WES] market, accounting for the largest market share in 2021. Because of the increasing prevalence of genetic and chronic disorders, such as Cancer, the aging population, increasing demand for targeted and personalized medicine, advanced technological healthcare framework, and favorable government initiatives. For instance, the American Hospital Association estimated that by 2030 around 170 million Americans will be suffering from at least one chronic disease. Furthermore, Cancer is second among the leading cause of death in the U.S. Every year in the United States, over 1.6 million people are diagnosed with Cancer, and nearly 600,000 die from it, making it the second leading cause of death. In addition, rising research activities and investment is estimated to drive industry size in the coming years. Investments in medical health R&D are on a surge, with an 11.1% growth in spending registered between 2019 to 2020. Moreover, United States (U.S.) medical and health research and development (R&D) investment reached $245.1 billion in 2020.

Competitive Landscape

The global whole exome sequencing market is highly competitive with many players. Some of the major players in the market are Illumina Inc., Bio-Rad Laboratories Inc., Agilent Technologies Inc., Macrogen Inc., Beijing Genomics Institute, Ambry Genetics Corp., Eurofins Scientific Group, F. Hoffmann-La Roche AG, GENEWIZ Inc., Pacific Biosciences of California Inc., among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Whole Exome Sequencing [WES] market globally. For instance, on 5 May 2022, Illumina partnered with Deerfield Management to accelerate drug development. Also, on August 03, 2022, Bio-Rad Acquired Curiosity Diagnostics.

Agilent Technologies, Inc.

Overview:

Agilent Technologies, Inc. is a leading life sciences company that provides instruments, software, services, and consumables for laboratory workflow. Agilent was established in 1999 and is headquartered in Santa Clara, California, United States.

Product Portfolio:

Agilent Technologies, Inc.'s product portfolio for Whole Exome Sequencing [WES] has a SureSelect Human All Exon V8, SureSelect Focused Exome, SureSelect Clinical Research Exome V2 and SureSelect non-human Exomes.

The global whole exome sequencing [WES] market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Increasing Adoption
      • 4.1.1.2. Increased Research and Development
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Skilled Professional
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product & Services

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services Segment
    • 7.1.2. Market Attractiveness Index, By Product & Services Segment
  • 7.2. Systems
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Kits
    • 7.3.1. Library Preparation Kits
    • 7.3.2. Target Enrichment Kits
    • 7.3.3. Others
  • 7.4. Services
    • 7.4.1. Sequencing Services
    • 7.4.2. Data Analysis (Bioinformatics) Services
    • 7.4.3. Others Services

8. By Technology

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
    • 8.1.2. Market Attractiveness Index, By Technology Segment
  • 8.2. Second-generation Sequencing
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Sequencing by Synthesis (SBS)
    • 8.2.4. Sequencing by Hybridization and Ligation (SBL)
  • 8.3. Third-generation Sequencing

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Drug Discovery and Development
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostics
  • 9.4. Personalized Medicine
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Agilent Technologies Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Illumina Inc.
  • 12.3. Bio-Rad Laboratories Inc.
  • 12.4. Macrogen Inc.
  • 12.5. Beijing Genomics Institute
  • 12.6. Ambry Genetics Corp.
  • 12.7. Eurofins Scientific Group
  • 12.8. F. Hoffmann-La Roche AG
  • 12.9. GENEWIZ Inc.
  • 12.10. Pacific Biosciences of California Inc.

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us